{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:50:14Z","timestamp":1792824614376,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ophtha.2019.03.019","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T01:31:56Z","timestamp":1553131916000},"page":"1350-1355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Assessing \u201cCell Therapy\u201d Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States"],"prefix":"10.1016","volume":"126","author":[{"given":"Rajinder S.","family":"Nirwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2199-9047","authenticated-orcid":false,"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-7467","authenticated-orcid":false,"suffix":"Jr.","given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay E.","family":"Kuriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ophtha.2019.03.019_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.ophtha.2019.03.019_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ophtha.2019.03.019_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9967","key":"10.1016\/j.ophtha.2019.03.019_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies","volume":"385","author":"Schwartz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2019.03.019_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ajo.2017.04.006","article-title":"Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration","volume":"179","author":"Ho","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2019.03.019_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell\u2013derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"Cruz","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.ophtha.2019.03.019_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","article-title":"Autologous induced stem-cell\u2013derived retinal cells for macular degeneration","volume":"376","author":"Mandai","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"435","key":"10.1016\/j.ophtha.2019.03.019_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4097","article-title":"A\u00a0bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration","volume":"10","author":"Kashani","year":"2018","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ophtha.2019.03.019_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.stem.2016.06.007","article-title":"Selling stem cells in the USA: assessing the direct-to-consumer industry","volume":"19","author":"Turner","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.ophtha.2019.03.019_bib11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMp1504560","article-title":"Medicine\u2019s Wild West\u2013unlicensed stem-cell clinics in the United States","volume":"373","author":"Taylor-Weiner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ophtha.2019.03.019_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMoa1609583","article-title":"Vision loss after intravitreal injection of autologous \u201cstem cells\u201d for AMD","volume":"376","author":"Kuriyan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ophtha.2019.03.019_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaophthalmol.2017.5453","article-title":"Vision loss secondary to autologous adipose stem cell injections: a rising problem","volume":"136","author":"Rong","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2019.03.019_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3928\/23258160-20160601-16","article-title":"Retinal detachment after subretinal stem cell transplantation","volume":"47","author":"Leung","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"9","key":"10.1016\/j.ophtha.2019.03.019_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3928\/23258160-20170829-16","article-title":"Bilateral retinal detachments after intravitreal injection of adipose-derived \u201cstem cells\u201d in a patient with exudative macular degeneration","volume":"48","author":"Saraf","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"6","key":"10.1016\/j.ophtha.2019.03.019_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jamaophthalmol.2016.0803","article-title":"Complication of autologous stem cell transplantation in retinitis pigmentosa","volume":"134","author":"Boudreault","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2019.03.019_bib17","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/stem.132","article-title":"Medicine on the fringe: stem cell-based interventions in advance of evidence","volume":"27","author":"Regenberg","year":"2009","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.ophtha.2019.03.019_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.stem.2016.07.015","article-title":"Global distribution of businesses marketing stem cell-based interventions","volume":"19","author":"Berger","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"10S","key":"10.1016\/j.ophtha.2019.03.019_bib19","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ophtha.2016.07.039","article-title":"Stem cell treatment: think twice if they ask for payment","volume":"123","author":"Parke","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.019_bib20","doi-asserted-by":"crossref","first-page":"xix","DOI":"10.1016\/j.ajo.2017.03.030","article-title":"The growing \u201cstem cell clinic\u201d problem","volume":"177","author":"Kuriyan","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"53","key":"10.1016\/j.ophtha.2019.03.019_bib21","doi-asserted-by":"crossref","first-page":"90636","DOI":"10.18632\/oncotarget.21891","article-title":"Unproven stem cell therapy for macular degeneration","volume":"8","author":"Ansari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ophtha.2019.03.019_bib22","series-title":"Homologous use of human cells, tissues, and cellular and tissue-based products. Draft guidance for industry and Food and Drug Administration staff","year":"2015"},{"key":"10.1016\/j.ophtha.2019.03.019_bib23","series-title":"Minimal manipulation of human cells, tissues and cellular and tissue-based products: draft guidance for industry and Food and Drug Administration staff","year":"2014"},{"key":"10.1016\/j.ophtha.2019.03.019_bib25","author":"US Food and Drug Administration"},{"issue":"8","key":"10.1016\/j.ophtha.2019.03.019_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2213-2600(18)30242-X","article-title":"Co-opting of ClinicalTrials.gov by patient-funded studies","volume":"6","author":"Wagner","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ophtha.2019.03.019_bib27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4103\/1673-5374.193251","article-title":"Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber\u2019s hereditary optic neuropathy","volume":"11","author":"Weiss","year":"2016","journal-title":"Neural Regen Res"},{"issue":"9","key":"10.1016\/j.ophtha.2019.03.019_bib28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4103\/1673-5374.191229","article-title":"Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment","volume":"11","author":"Weiss","year":"2016","journal-title":"Neural Regen Res"},{"issue":"9","key":"10.1016\/j.ophtha.2019.03.019_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4103\/1673-5374.165525","article-title":"Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy","volume":"10","author":"Weiss","year":"2015","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ophtha.2019.03.019_bib30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/sci.2017.11.05","article-title":"Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION)","volume":"4","author":"Weiss","year":"2017","journal-title":"Stem Cell Investig"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018326307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018326307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:07:15Z","timestamp":1758982035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018326307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0161642018326307"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.019","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing \u201cCell Therapy\u201d Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}